Condition
Scopolamine
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Edaravone
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 2 (1)
Trial Status
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Edaravone1
- Scopolamine1
- Scopolamine Atropine Edaravone And Dexmedetomidine1
Active Sponsors
- Dartmouth-Hitchcock Medical Center1
- Ruijin Hospital1
Top Investigators
Dartmouth-Hitchcock Medical Center
Department of Neurology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Related Conditions
- Amyotrophic Lateral Sclerosis1
- Respiratory Function1
- Motion Sickness1